Stanley Druckenmiller's VRNA Position Overview
Stanley Druckenmiller (via Duquesne Family Office LLC) currently holds 1 M shares of Verona Pharma plc (VRNA) worth $106.93 M, representing 2.63% of the portfolio. First purchased in 2024-Q3, this short-term holding has been held for 5 quarters.
Based on 13F filings, Stanley Druckenmiller has maintained this position in VRNA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2024, adding 201,535 shares.
Analysis based on 13F filings available since 2013 Q2
Stanley Druckenmiller's Verona Pharma plc (VRNA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Verona Pharma plc (VRNA) Trades by Stanley Druckenmiller
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2024 | +686,045 | New Buy | 686,045 | $28.77 |
| Q4 2024 | +201,535 | Add 29.38% | 887,580 | $46.44 |
| Q1 2025 | +114,500 | Add 12.90% | 1 M | $63.49 |
Stanley Druckenmiller's Verona Pharma plc Investment FAQs
Stanley Druckenmiller first purchased Verona Pharma plc (VRNA) in Q3 2024, acquiring 686,045 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Stanley Druckenmiller has held Verona Pharma plc (VRNA) for 5 quarters since Q3 2024.
Stanley Druckenmiller's largest addition to Verona Pharma plc (VRNA) was in Q3 2024, adding 686,045 shares worth $19.74 M.
According to the latest 13F filing for Q3 2025, Stanley Druckenmiller's firm, Duquesne Family Office LLC, owns 1,002,080 shares of Verona Pharma plc (VRNA), valued at approximately $106.93 M.
As of the Q3 2025 filing, Verona Pharma plc (VRNA) represents approximately 2.63% of Stanley Druckenmiller's publicly disclosed stock portfolio, making it one of their key holdings.
Stanley Druckenmiller's peak holding in Verona Pharma plc (VRNA) was 1,002,080 shares, as reported at the end of Q1 2025.